6.99
+4.33(+162.78%)
Currency In USD
| Previous Close | 2.66 |
| Open | 8.42 |
| Day High | 9.88 |
| Day Low | 6.15 |
| 52-Week High | 12.32 |
| 52-Week Low | 1.94 |
| Volume | 139.79M |
| Average Volume | 2.35M |
| Market Cap | 10.44M |
| PE | -5.68 |
| EPS | -1.23 |
| Moving Average 50 Days | 3.14 |
| Moving Average 200 Days | 4.05 |
| Change | 4.33 |
If you invested $1000 in Evoke Pharma, Inc. (EVOK) 10 years ago, it would be worth $8.29 as of July 10, 2025 at a share price of $6.99. Whereas If you bought $1000 worth of Evoke Pharma, Inc. (EVOK) shares 5 years ago, it would be worth $13.98 as of July 10, 2025 at a share price of $6.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036
GlobeNewswire Inc.
Yesterday at 12:16 PM GMT
Extends patent exclusivity period an additional 6 years once grantedSOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025
GlobeNewswire Inc.
Apr 28, 2025 12:30 PM GMT
SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstrac
Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025
GlobeNewswire Inc.
Mar 06, 2025 1:30 PM GMT
SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today